Novo Nordisk’s Pipeline Successor Outperforms Flagship Weight-Loss Drug
New clinical data shows UBT251 leads to 9.8% weight loss vs. semaglutide’s 4.8%, as Novo Nordisk expands its…
Novo Nordisk Seeks Growth Beyond Flagship Drugs with New Obesity Pill Trial
Novo Nordisk starts Phase 1 trial for oral obesity drug LX9851, a strategic move to diversify beyond GLP-1…
OnePlus 15T bets on G2 esports chip for stable gaming performance
ⓘ OnePlus The OnePlus 15T is said to sport a 360° surround high-performance antenna setup. Pictured: the phone…